<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BIORXIV</journal-id>
<journal-title-group>
<journal-title>bioRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/084913</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="author-type">
<subject>Regular Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>New Results</subject>
</subj-group>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Neuroscience</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A modification-specific peptide-based immunization approach using CRM197 carrier protein: <italic>Development of a selective vaccine against pyroglutamate A&#x03B2; peptides</italic></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Vingtdeux</surname>
<given-names>Val&#x00E9;rie</given-names>
</name>
<xref ref-type="author-notes" rid="n1">&#x0023;</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Haitian</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chandakkar</surname>
<given-names>Pallavi</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Acker</surname>
<given-names>Christopher M.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Davies</surname>
<given-names>Peter</given-names>
</name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8983-1497</contrib-id>
<name>
<surname>Marambaud</surname>
<given-names>Philippe</given-names>
</name>
</contrib>
<aff id="a1"><institution>The Litwin-Zucker Research Center for the Study of Alzheimer&#x2019;s Disease, The Feinstein Institute for Medical Research</institution>, Manhasset, New York, 11030 <country>USA</country></aff>
</contrib-group>
<author-notes>
<fn id="n1" fn-type="present-address"><label>&#x0023;</label><p>Present address: INSERM, UMR1172 Jean-Pierre Aubert research centre; Universit&#x00E9; de Lille, Facult&#x00E9; de M&#x00E9;decine; CHRU-Lille, 59045 Lille, France.</p></fn>
<corresp>Corresponding author: Philippe Marambaud, Email address: <email>PMaramba@northwell.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<year>2016</year>
</pub-date>
<elocation-id>084913</elocation-id>
<history>
<date date-type="received">
<day>04</day>
<month>11</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>04</day>
<month>11</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2016, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2016</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="084913.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>ABSTRACT</title>
<p>Strategies aimed at reducing cerebral accumulation of the amyloid-&#x03B2; (A&#x03B2;) peptides have therapeutic potential in Alzheimer&#x2019;s disease (AD). A&#x03B2; immunization has proven to be effective at promoting A&#x03B2; clearance in animal models but adverse effects have hampered its clinical evaluation. The first anti-A&#x03B2; immunization clinical trial, which assessed a full-length A&#x03B2;1-42 vaccine, increased the risk of encephalitis most likely because of autoimmune pro-inflammatory T helper 1 (Th1) response against all forms of A&#x03B2;. Immunization against less abundant but potentially more pathologically relevant A&#x03B2; products, such as N-terminally-truncated pyroglutamate-3 A&#x03B2; (A&#x03B2;pE3), could provide efficacy and improve tolerability in A&#x03B2; immunotherapy. Here, we describe a selective vaccine against A&#x03B2;pE3 using the diphtheria toxin mutant CRM197 as carrier protein for epitope presentation. CRM197 is currently used in licensed vaccines and has demonstrated excellent immunogenicity and safety in humans. In mice, our A&#x03B2;pE3:CRM197 vaccine triggered the production of specific anti-A&#x03B2;pE3 antibodies that did not cross-react with A&#x03B2;1-42, non-cyclized A&#x03B2;E3, or N-terminally-truncated pyroglutamate-11 A&#x03B2; (A&#x03B2;pE11). A&#x03B2;pE3:CRM197 antiserum strongly labeled A&#x03B2;pE3 in insoluble protein extracts and decorated cortical amyloid plaques in human AD brains. Anti-A&#x03B2;pE3 antibodies were almost exclusively of the IgG1 isotype, suggesting an anti-inflammatory Th2 response bias to the A&#x03B2;pE3:CRM197 vaccine. To the best of our knowledge, this study shows for the first time that CRM197 has potential as a safe and suitable vaccine carrier for active and selective immunization against specific protein sequence modifications or conformations, such as A&#x03B2;pE3.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>Alzheimer&#x2019;s disease</kwd>
<kwd>pyroglutamate-3 A&#x03B2;</kwd>
<kwd>CRM197</kwd>
<kwd>active immunization</kwd>
<kwd>modification-specific peptide-based immunization.</kwd>
</kwd-group>
<counts>
<page-count count="23"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>INTRODUCTION</title>
<p>Anti-amyloid-&#x03B2; (A&#x03B2;) immunotherapy is under intense investigation in Alzheimer&#x2019;s disease (AD) (<xref ref-type="bibr" rid="c18">Lemere 2013</xref>; <xref ref-type="bibr" rid="c43">Wisniewski &#x0026; Go&#x00F1;i 2015</xref>). A&#x03B2; is the core component of the amyloid plaques, a hallmark of the AD brain, and mutations in its precursor APP or in presenilins&#x2014;the catalytic components of the A&#x03B2;-producing enzyme &#x03B3;-secretase&#x2014;cause familial AD (<xref ref-type="bibr" rid="c5">Checler 1995</xref>; <xref ref-type="bibr" rid="c19">Marambaud &#x0026; Robakis 2005</xref>; <xref ref-type="bibr" rid="c34">Selkoe 2001</xref>). Thus, strategies aimed at preventing or lowering A&#x03B2; cerebral accumulation might interfere with AD pathogenesis (<xref ref-type="bibr" rid="c6">Citron 2010</xref>). A&#x03B2; immunization has proven to be very effective at promoting A&#x03B2; clearance, at least in animal models. Preclinical and clinical studies, however, have been hampered by unforeseen side effects. The first clinical trial AN-1792, which evaluated an A&#x03B2;1-42/QS21 vaccine, was halted in phase II when about 6&#x0025; of the patients developed meningoencephalitis (<xref ref-type="bibr" rid="c16">Holmes et al. 2008</xref>). Although the exact mechanism that led to acute brain inflammation in this clinical trial remains unclear, it is believed that encephalitis arose from an autoimmune reaction triggered by a vaccine directed against the abundant self-protein A&#x03B2; coupled to the strong adjuvant QS21, thus favoring pro-inflammatory T helper 1 (Th1) immune responses (<xref ref-type="bibr" rid="c38">Tabira 2010</xref>). In this context, second generation anti-A&#x03B2; vaccines were designed to prevent T-cell responses during anti-A&#x03B2; immunization. These vaccines tested, for instance, N-terminal epitopes within the A&#x03B2; sequence and adjuvants that minimize T-cell engagement and favor B-cell responses (<xref ref-type="bibr" rid="c43">Wisniewski &#x0026; Go&#x00F1;i 2015</xref>). Another approach is passive immunization, which has the advantage to bypass T-cell engagement and allow a better control of monoclonal antibody (mAb) dosage and epitope targeting. However, recent phase III AD trials of two anti-A&#x03B2; mAb, solanezumab and bapineuzumab, failed to slow cognitive or functional decline in patients with mild-to-moderate AD (<xref ref-type="bibr" rid="c14">Hampel et al. 2015</xref>). The main argument put forward to explain the lack of efficacy of these passive immunization approaches was that treatment might have started too late to reverse or delay the disease process (<xref ref-type="bibr" rid="c17">Karran &#x0026; Hardy 2014</xref>). It is also possible that passive immunization might not deliver enough mAb to promote plaque clearance. Passive immunization also raised concerned because of the practical and financial sustainability of injecting and monitoring mAb injections on a regular basis for several years (<xref ref-type="bibr" rid="c12">Golde 2014</xref>).</p>
<p>In the amyloidogenic pathway, APP is sequentially endoproteolyzed by the proteases &#x03B2;-secretase/BACE1 and the presenilin/&#x03B3;-secretase complex to produce various A&#x03B2; peptides, including the most abundant isoforms A&#x03B2;1-40 and A&#x03B2;1-42 (<xref ref-type="bibr" rid="c9">De Strooper et al. 2010</xref>). In addition to these major A&#x03B2; isoforms, N-terminally truncated A&#x03B2; products have been identified in the AD brain, including peptides starting with pyroglutamate residues at the position 3 (A&#x03B2;pE3) and 11 (A&#x03B2;pE11) (<xref ref-type="bibr" rid="c21">Mori et al. 1992</xref>; <xref ref-type="bibr" rid="c25">Portelius et al. 2010</xref>; <xref ref-type="bibr" rid="c29">Saido et al. 1995</xref>). N-terminal truncation was proposed to be mediated, at least in part, by aminopeptidase A (<xref ref-type="bibr" rid="c35">Sevalle et al. 2009</xref>) and cyclization of N-terminally-exposed glutamates is catalyzed by the enzyme glutaminyl cyclase (<xref ref-type="bibr" rid="c31">Schilling et al. 2008</xref>). Pyroglutamate A&#x03B2; is a promising target because appears to play a key role in A&#x03B2; oligomerization, seeding, and stabilization (<xref ref-type="bibr" rid="c8">Dammers et al. 2015</xref>; <xref ref-type="bibr" rid="c15">He &#x0026; Barrow 1999</xref>; <xref ref-type="bibr" rid="c22">Nussbaum et al. 2012</xref>; <xref ref-type="bibr" rid="c24">Piccini et al. 2005</xref>; <xref ref-type="bibr" rid="c30">Schilling et al. 2006</xref>; <xref ref-type="bibr" rid="c32">Schlenzig et al. 2009</xref>). Furthermore, pyroglutamate A&#x03B2; has specific neurotoxic properties in cell cultures and leads to cerebral neuronal loss and synaptic function impairments in mice (<xref ref-type="bibr" rid="c1">Alexandru et al. 2011</xref>; <xref ref-type="bibr" rid="c13">Gunn et al. 2016</xref>; <xref ref-type="bibr" rid="c28">Russo et al. 2002</xref>; <xref ref-type="bibr" rid="c33">Schlenzig et al. 2012</xref>).</p>
<p>In this context, recent studies have proposed that immunization against less abundant but potentially more amyloidogenic and more neurotoxic isoforms of A&#x03B2;, such as A&#x03B2;pE3, could improve tolerability and efficacy in A&#x03B2; immunotherapy (<xref ref-type="bibr" rid="c2">Bayer &#x0026; Wirths 2014</xref>; <xref ref-type="bibr" rid="c7">Cynis et al. 2016</xref>; <xref ref-type="bibr" rid="c11">Frost et al. 2015</xref>). These studies, however, are so far limited to passive immunization using antibodies previously screened <italic>in vitro</italic> for their specificity to A&#x03B2;pE3 and non-cross-reactivity to full length A&#x03B2;. Here, we describe a novel A&#x03B2;pE3 vaccine using the non-toxic mutant of diphtheria toxin CRM197 (cross-reacting material 197) as carrier protein for epitope presentation. CRM197 has been extensively used in licensed vaccines directed against capsular polysaccharides of several bacterial pathogens and has demonstrated excellent efficacy and tolerability in humans (<xref ref-type="bibr" rid="c3">Br&#x00F6;ker et al. 2011</xref>; <xref ref-type="bibr" rid="c36">Shinefield 2010</xref>). Because recent data have shown that CRM197 is also suitable for conjugation to, and presentation of, peptides (<xref ref-type="bibr" rid="c4">Caro-Aguilar et al. 2013</xref>), we speculated that CRM197 could be conjugated to minimal peptide epitopes to facilitate the generation of conformation/modification-specific antibodies directed against pyroglutamate A&#x03B2;. We show that our vaccines in mice&#x2014;composed of A&#x03B2;pE3-8 or A&#x03B2;pE11-16 peptides covalently conjugated to CRM197&#x2014;triggered the production of fully specific antibodies directed against A&#x03B2;pE3 and A&#x03B2;pE11, respectively. Anti-A&#x03B2;pE3 antibodies stained brains from AD patients by western blotting (WB) and immunohistochemistry (IHC), and were almost exclusively of the IgG1 isotype, indicating the engagement of a Th2 response.</p>
</sec>
<sec id="s2">
<title>MATERIALS AND METHODS</title>
<sec id="s2a">
<title>Preparation of the A&#x03B2;pE3-8:CRM197 and A&#x03B2;pE11-16:CRM197 conjugate vaccines</title>
<p>N-terminally acetylated and C-terminally amidated A&#x03B2;pE3-8 and A&#x03B2;pE11-16 peptides containing a C-terminal cysteine residue preceded by a two-glycine-bridge (pEFRHDSGGC and pEVHHQKGGC, respectively; GenScript) were solubilized in phosphate buffered saline (PBS) containing 2 mM EDTA (PBS/EDTA) to obtain 4 mg/mL solutions. CRM197 (List Biological Labs) was reconstituted with PBS/EDTA to obtain a 2 mg/mL solution. To irreversibly crosslink the peptides to the carrier protein, CRM197 was first activated with a 20-fold molar excess of succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) crosslinker (Pierce, at 1.5 mg/mL in DMSO). After a 30 min incubation at room temperature (RT), the SMCC/CRM197 mixture was desalted on a resin column (Zeba Desalt Spin Column, Pierce). Activated CRM197 was then combined with A&#x03B2;pE3-8 and A&#x03B2;pE11-16 peptide solutions and incubated for 30 min at RT. A ratio of 1:10 (CRM197 to peptides) was empirically chosen. Successful conjugation was confirmed by SDS-PAGE and coomassie staining (GelCode, Pierce, see <xref ref-type="fig" rid="fig2">Fig. 2A</xref>).</p>
</sec>
<sec id="s2b">
<title>Immunization and sample collection</title>
<p>Animal experiments were performed according to procedures approved by the Feinstein Institute for Medical Research Institutional Animal Care and Use Committee. C57BL/6J male mice (&#x007E;3-month-old) were injected subcutaneously with 10 &#x03BC;g of A&#x03B2;pE3-8:CRM197 and A&#x03B2;pE11-16:CRM197 conjugate vaccines or with 10 &#x03BC;g of free A&#x03B2;pE3-8 and A&#x03B2;pE11-16 peptides, used as negative controls. A prime injection (Day 0) was followed by a boost injection at Day 14 of the same amount of vaccines or free peptides. Blood samples were taken at Day 0 and Day 30.</p>
</sec>
<sec id="s2c">
<title>ELISA for measurement of antibody responses</title>
<p>Anti-A&#x03B2;pE3-8, anti-A&#x03B2;pE11-16, and anti-CRM197 antibody levels in mouse serum were determined by enzyme-linked immunosorbent assay (ELISA). 96-well plates (Maxisorp, Nunc) were coated with 100 &#x03BC;L of 2 &#x03BC;g/mL A&#x03B2;pE3-8, A&#x03B2;pE11-16, or CRM197 in carbonate buffer (0.05 M, pH 9.6) and incubated overnight at 4<sup>o</sup>C. The following morning, plates were blocked for 1 h at RT with 5&#x0025; skim milk in TBS containing 0.05&#x0025; Tween 20 (TBST). After washing with TBST, serial dilutions of individual mouse serum samples (diluted in PBST containing 1&#x0025; skim milk) were prepared and 100 &#x03BC;L/well of mouse serum was incubated for 2 h at RT. After 5 more washes, 100 &#x03BC;L/well horseradish peroxidase (HRP)-conjugated goat anti-mouse immunoglobins (Igs) secondary antibody (Southern Biotech, diluted 1:500 in PBST containing 1&#x0025; skim milk) was incubated for 1 h at RT. TMB substrate was added after another wash and the reaction was allowed to develop for 30 min at RT. The optical density was measured at 405 nm using a TECAN GENios Pro plate reader. Antibody responses were expressed as titers. Antibody titers were determined via a linear fit for optical density values of 9 dilutions, and expressed in arbitrary units by calculating the reciprocal dilution that gave 50&#x0025; of the maximum absorbance response. For measurement of Ig isotype specificity (IgG1, IgG2b, IgG2c, IgG3, IgA, and IgM), an ELISA protocol similar to that described above was followed. Briefly, ELISA plates were coated as described above. Reference mouse IgG1, IgG2b, IgG2c, IgG3, IgA and IgM antibodies were diluted in TBST containing 1&#x0025; skim milk. To detect specific binding, HRP-conjugated anti-mouse IgG1, IgG2b, IgG2c, IgG3, IgA and IgM antibodies (Southern Biotech) were used at a dilution of 1:500, TMB was then added as described above. The presence of antigen-specific isotype-specific antibodies was detected and measured as described above. Antibody levels were expressed in micrograms per milliliter.</p>
</sec>
<sec id="s2d">
<title>Statistical analysis</title>
<p>For comparison of results within experimental groups, a Student&#x2019;s t test was performed. For all multigroup comparisons, one-way analysis of variance (ANOVA) and post-hoc Bonferoni test for multiple comparisons were used. Statistical significance was defined as p &#x003C; 0.05.</p>
</sec>
<sec id="s2e">
<title>Human cases and brain protein extraction</title>
<p>Cases were obtained from the Albert Einstein College of Medicine human brain bank, Bronx, NY (see Table). Brain samples (see Table) were processed as previously described (<xref ref-type="bibr" rid="c40">Vingtdeux et al. 2011</xref>). Briefly, human brains were sequentially extracted to obtain a soluble SDS fraction and an insoluble formic acid (FA) fraction. Samples were first homogenized and sonicated in Tris-buffered saline (TBS) containing 2&#x0025; SDS and 1x Complete protease inhibitor mixture (Roche Applied Science) and centrifuged at 100,000 x <italic>g</italic> for 1 h at 4&#x00B0;C. The supernatant was removed and the resulting pellet was then extracted with 70&#x0025; formic acid in water. FA extracts were dried under vacuum in a speed vacuum and thus dissolved in DMSO.</p>
</sec>
<sec id="s2f">
<title>Western blot (WB)</title>
<p>Protein extracts from SDS and FA fractions obtained from human brain samples were analyzed by SDS-PAGE using the indicated antibodies. Samples were electrophoresed on 10&#x0025; Tris-HCl gels (phospho-tau and actin analysis) or on 16.5&#x0025; Tris-Tricine gels (A&#x03B2; isoforms, Biorad) and transferred onto nitrocellulose membranes. A&#x03B2; was detected as previously described (<xref ref-type="bibr" rid="c39">Vingtdeux et al. 2015</xref>). Briefly, membranes were microwaved for 5 min in PBS. Membranes were then blocked in 5&#x0025; fat-free milk in TBS, and incubated with primary antibodies overnight at 4&#x00B0;C. A standard ECL detection procedure was then used.</p>
</sec>
<sec id="s2g">
<title>Immunohistochemistry (IHC)</title>
<p>Five-&#x03BC;m-thick sections of formalin-fixed paraffin-embedded brain tissue were immunostained with 6E10 mAb (Covance, 1:1000 dilution) or A&#x03B2;pE3:CRM197 antiserum (1:2 dilution). Sections were deparaffinized by immersion in xylene and hydration through graded ethanol solutions. Denaturation for antigen recovery was performed by incubation of the slides in 70&#x0025; formic acid for 30 min at RT. Denaturation was stopped by incubation in 100 mM Tris-HCl, pH 7.4 for 5 min. After washing once in TBS containing 0.05&#x0025; Triton-X100 (TBSTx), endogenous peroxidase activity was inhibited by incubation in 5&#x0025; hydrogen peroxide in TBSTx for 30 min at RT. After washing twice in TBSTx for 5 min and once in water, sections were blocked in 10&#x0025; fat-free milk (6E10) or 5&#x0025; normal goat serum (A&#x03B2;pE3:CRM197 antiserum) in TBSTx containing 1 mg/mL BSA and 1 mM NaF for 1 h at RT. Sections were then incubated in the presence of primary antibodies diluted in 10&#x0025; fat-free milk (6E10) or 5&#x0025; normal goat serum (A&#x03B2;pE3:CRM197 antiserum) in TBSTx containing 1 mg/ml BSA and 1 mM NaF overnight at 4<sup>o</sup>C in a humidified chamber. After washing, the sections were incubated with biotin-coupled anti-mouse IgG1 secondary antibodies (1:1,000 dilution in TBSTx with 20&#x0025; Superblock, Pierce) before incubation with streptavidin-HRP (1:1,000 dilution in TBSTx with 20&#x0025; Superblock, Southern Biotech) and visualization with diaminobenzidine tetrahydrochloride.</p>
</sec>
</sec>
<sec id="s3">
<title>RESULTS</title>
<sec id="s3a">
<title>Immunogenicity of CRM197 in mice</title>
<p>We first verified that unconjugated CRM197 without adjuvant was immunogenic in C57BL/6J mice. Based on previously published dose-ranging immunogenicity analyses of different CRM197-based vaccines (<xref ref-type="bibr" rid="c4">Caro-Aguilar et al. 2013</xref>; <xref ref-type="bibr" rid="c27">Rondini et al. 2011</xref>), we choose to inject 10 &#x03BC;g of CRM197. A prime injection of unconjugated CRM197 followed by a boost injection at Day 15 of the same amount of carrier protein elicited robust immunogenicity against CRM197 at Day 30 (<xref ref-type="fig" rid="fig1">Fig. 1A</xref>). Saline control injections as expected did not elicit an anti-CRM197 antibody response (<xref ref-type="fig" rid="fig1">Fig. 1A</xref>). Ig isotype determination revealed that anti-CRM197 antibodies were exclusively of the IgG1 isotype and reached levels of &#x007E;35 &#x03BC;g/mL at Day 30 post-prime injection (<xref ref-type="fig" rid="fig1">Fig. 1B</xref>).</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1:</label>
<caption><title>Anti-CRM197 antibody response in mice immunized with CRM197</title>
<p>Specific anti-CRM197 Ig titers (A) and Ig isotype concentration (IgG1, IgG2a, IgG2b, IgG3, IgA, IgM) (B) quantified by ELISA in sera obtained from C57BL/6J mice immunized (CRM197) or not (Saline) with CRM197. Sera were collected 30 days after prime injection. Data are mean &#x00B1; SEM from 6 mice per group, each dot represent individual mouse serum.</p></caption>
<graphic xlink:href="084913_fig1.tif"/>
</fig>
</sec>
<sec id="s3b">
<title>Immunogenicity of the A&#x03B2;pE3:CRM197 and A&#x03B2;pE11:CRM197 conjugate vaccines</title>
<p>A short peptide sequence of 6 residues starting at pE3 (pE3-8) or pE11 (pE11-16) linked in C-terminal to a 3-residue spacer (see Methods) was chosen to facilitate the production of conformation/modification-specific antibodies directed against A&#x03B2;. A 6-residue peptide epitope has also the advantage to be shorter than conventional T-cell epitopes and thus might prevent unwanted T-cell activation and detrimental pro-inflammatory responses (<xref ref-type="bibr" rid="c26">Rammensee 1995</xref>). Molecular weight analysis by protein staining after SDS-PAGE revealed that pE3-8 and pE11-16 peptides could be covalently conjugated to CRM197 (<xref ref-type="fig" rid="fig2">Fig. 2A</xref>). The generated A&#x03B2;pE3:CRM197 and A&#x03B2;pE11:CRM197 conjugates (10 &#x03BC;g) elicited robust antibody responses against A&#x03B2;pE3-8 and A&#x03B2;pE11-16 peptides, respectively, when assessed by ELISA. Total serum Ig titers were in average of 1,000 at Day 30 after one prime injection and one boost injection at Day 15 (<xref ref-type="fig" rid="fig2">Figs. 2B</xref> and <xref ref-type="fig" rid="fig2">2D</xref>). Importantly, the vaccines did not generate antibodies directed against the corresponding non-cyclized A&#x03B2;3-8 and A&#x03B2;11-16 peptides (<xref ref-type="fig" rid="fig2">Figs. 2C</xref> and <xref ref-type="fig" rid="fig2">2E</xref>), showing that immunogenicity was specific to the pE modification. No anti-A&#x03B2;pE3- or anti-A&#x03B2;pE11-specific antibodies were detected in control mice injected with unconjugated CRM197 or saline (<xref ref-type="fig" rid="fig2">Figs. 2B</xref> and <xref ref-type="fig" rid="fig2">2D</xref>). Injection of free A&#x03B2;pE3-8 and A&#x03B2;pE11-16 peptides (unconjugated to CRM197) did not elicit immunogenic responses against these peptides (<xref ref-type="fig" rid="fig2">Figs. 2B</xref> and <xref ref-type="fig" rid="fig2">2D</xref>).</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2:</label>
<caption><title>Anti-A&#x03B2;pE3-9 and anti-A&#x03B2;pE11-16 antibody response</title>
<p>Coomassie blue staining of CRM197 alone or conjugated to A&#x03B2;pE3-9 (A&#x03B2;pE3-9:CRM197) or A&#x03B2;pE11-16 (A&#x03B2;pE11-16:CRM197) (A). Anti-A&#x03B2;pE3-9 (B), anti-A&#x03B2;3-9 (C), anti-A&#x03B2;pE11-16 (D), and anti-A&#x03B2;11-16 (E) Ig titers in sera obtained from mice immunized with A&#x03B2;pE3-9 or A&#x03B2;pE11-16 conjugated (A&#x03B2;pE3-9:CRM197, A&#x03B2;pE11-16:CRM197) or not (A&#x03B2;pE3-9, A&#x03B2;pE11-16) with CRM197. Data represents mean &#x00B1; SEM from 3-9 mice per group. MW, molecular weight makers.</p></caption>
<graphic xlink:href="084913_fig2.tif"/>
</fig>
<p>As observed for the immunogenic responses to unconjugated CRM197 (<xref ref-type="fig" rid="fig1">Fig. 1</xref>), the anti-A&#x03B2;pE3 and anti-A&#x03B2;pE11 antibodies were exclusively of the IgG1 isotype (<xref ref-type="fig" rid="fig3">Figs. 3A</xref> and <xref ref-type="fig" rid="fig3">3B</xref>). At Day 30 post-prime injection, A&#x03B2;pE3:CRM197 and A&#x03B2;pE11:CRM197 vaccines elicited the production of &#x007E;1.5 &#x03BC;g/mL of serum specific IgG1.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3:</label>
<caption><title>Isotype specificity of the Ig response elicited by A&#x03B2;pE3-9:CRM197 and A&#x03B2;pE11-16:CRM197 vaccines</title>
<p>Anti-A&#x03B2;pE3-9 (A) or anti-A&#x03B2;pE11-16 Ig isotype (IgG1, IgG2a, IgG2b, IgG3, IgA, IgM) concentrations in sera obtained from mice immunized with A&#x03B2;pE3-9 or A&#x03B2;pE11-16 conjugated (A&#x03B2;pE3-9:CRM197, A&#x03B2;pE11-16:CRM197) or not (AbpE3-9, AbpE11-16) with CRM197 (B). Data represents mean &#x00B1; SEM from 3-7 mice per group.</p></caption>
<graphic xlink:href="084913_fig3.tif"/>
</fig>
</sec>
<sec id="s3c">
<title>The A&#x03B2;pE3:CRM197 vaccine produces antibodies that react with amyloid deposits in AD brains</title>
<p>Antiserum produced after immunization with the A&#x03B2;pE3:CRM197 vaccine labeled synthetic A&#x03B2;pE3-42 peptide by WB (<xref ref-type="fig" rid="fig4">Fig. 4A</xref>). Importantly, A&#x03B2;pE3:CRM197 antiserum did not cross-react with synthetic A&#x03B2;pE11-42 or synthetic A&#x03B2;1-42 (<xref ref-type="fig" rid="fig4">Fig. 4A</xref>), showing that the antibodies produced did not recognize non-specifically the pE modification nor they interacted with an internal epitope containing residues 3-8 of A&#x03B2;1-42. A&#x03B2;pE3:CRM197 antiserum is thus fully specific to 241 A&#x03B2;pE3. Strikingly, A&#x03B2;pE3:CRM197 antiserum was also able to label A&#x03B2;pE3 in insoluble/aggregated brain protein preparations (FA fractions, see Methods) obtained from 6 independent well-characterized AD patients (see Table). Almost no immunoreactivity was observed in the corresponding soluble preparations (SDS fractions) (<xref ref-type="fig" rid="fig4">Fig. 4B</xref>), indicating that the anti-A&#x03B2;pE3 antibodies produced by the A&#x03B2;pE3:CRM197 vaccine recognize human amyloid 246 material in the AD brain, and that A&#x03B2;pE3 is mostly aggregated. Of note, A&#x03B2;pE3 immunoreactivity was also observed in normal control brains that contained large amounts of aggregated total A&#x03B2; (also detected with 6E10 mAb in the insoluble fractions) (<xref ref-type="fig" rid="fig4">Fig. 4B</xref>). In fact, a strong parallel was observed between the levels of aggregated total A&#x03B2; and aggregated A&#x03B2;pE3 in brains from both normal and AD individuals (<xref ref-type="fig" rid="fig4">Fig. 4B</xref>), suggesting that A&#x03B2;pE3 is a marker for amyloid deposition but is not specific to AD.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4:</label>
<caption><title>A&#x03B2;pE3-9:CRM197 antiserum characterization</title>
<p>WB analysis of recombinant A&#x03B2;1-42, A&#x03B2;pE3-42, and A&#x03B2;pE11-42 using 6E10, 4G8, or A&#x03B2;pE3-9:CRM197 antiserum showing the specificity of the A&#x03B2;pE3-9:CRM197 antiserum towards A&#x03B2;pE3-42 (A). WB analysis of human brain homogenates obtained from normal or AD cases (Braak stage V-VI, see Table) using PHF1, actin, and 6E10 antibodies, or A&#x03B2;pE3-9:CRM197 antiserum (B). IHC of serial brain sections from an AD case stained with 6E10 antibody or A&#x03B2;pE3-9:CRM197 antiserum (C).</p></caption>
<graphic xlink:href="084913_fig4.tif"/>
</fig>
<p>In addition, A&#x03B2;pE3:CRM197 antiserum decorated amyloid plaques in human AD brain slices by IHC. Most of the anti-A&#x03B2;pE3 immunoreactivity was observed on plaques present in the cortex (entorhinal and parahippocampal cortices, <xref ref-type="fig" rid="fig4">Fig. 4C</xref>). Although amyloid plaque deposition was very pronounced in the AD case analyzed, only a few plaques were labeled with the A&#x03B2;pE3:CRM197 antiserum in the hippocampal formation (the dentate gyrus, CA1, and subiculum, <xref ref-type="fig" rid="fig4">Fig.4C</xref>). Interestingly, in adjacent sections of the parahippocampal cortex, identical plaques stained for both total A&#x03B2; (6E10 mAb) and A&#x03B2;pE3 (<xref ref-type="fig" rid="fig4">Fig. 4C</xref>, arrows). This co-staining revealed that anti-A&#x03B2;pE3 antiserum preferentially decorated highly dense plaques. Of note, anti-IgG1 secondary antibodies were used in combination with A&#x03B2;pE3:CRM197 antiserum for WB and IHC further showing that the immunoreactive anti-A&#x03B2;pE3 antibodies are of the IgG1 isotype.</p>
</sec>
</sec>
<sec id="s4">
<title>DISCUSSION</title>
<p>In this study, we show that minimal epitopes can be designed to generate vaccines that are fully specific to the pyroglutamate modifications of A&#x03B2;. Indeed, antiserum obtained after immunization with the A&#x03B2;pE3:CRM197 conjugate vaccine, demonstrated excellent immunoreactivity against synthetic and AD brain-derived A&#x03B2;pE3, with no detectable cross-reactivity with A&#x03B2;1-42, non-cyclized A&#x03B2;E3, or A&#x03B2;pE11. Further analysis using AD brain samples revealed that A&#x03B2;pE3:CRM197 antiserum mainly decorated highly aggregated amyloid material, supporting the notion that A&#x03B2;pE3 is associated with the dense core of the senile plaques (<xref ref-type="bibr" rid="c37">Sullivan et al. 2011</xref>).</p>
<p>CRM197 is routinely used as conjugate vaccine in licensed vaccines directed against bacterial capsular polysaccharides (<xref ref-type="bibr" rid="c3">Br&#x00F6;ker et al. 2011</xref>; <xref ref-type="bibr" rid="c36">Shinefield 2010</xref>). The use of CRM197 for peptide epitope presentation has not been approved yet for human use, but pre-clinical evidence has already suggested that it has therapeutic potential (<xref ref-type="bibr" rid="c4">Caro-Aguilar et al. 2013</xref>). In addition, an experimental vaccine against A&#x03B2; using CRM197 is currently being evaluated in a Phase II trial (ACC-001, Elan/J&#x0026;J/Wyeth). In the ACC-001 vaccine, CRM197 is conjugated to the N-terminal residues 1-6 of A&#x03B2; and thus is aimed at targeting all A&#x03B2; isoforms containing this N-end of A&#x03B2; (<xref ref-type="bibr" rid="c41">Winblad et al. 2014</xref>). Our study strengthens the notion that CRM197 has strong potential for peptide presentation. This work further demonstrates that CRM197 might particularly be useful for the generation of conformation/modification-specific anti-peptide vaccines.</p>
<p>Both active and passive immunization directed against A&#x03B2; have their respective pros and cons (see Introduction) and there is no consensus yet as to whether one approach has a stronger therapeutic potential for AD. Both approaches&#x2014;targeting different A&#x03B2; epitopes&#x2014;are therefore actively investigated at the pre-clinical and clinical levels. Our approach was aimed at increasing the anti-A&#x03B2; immunotherapy toolkit by proposing an active immunization strategy specifically targeting N-terminally-truncated pyroglutamate A&#x03B2;. Further studies will be required to validate the utility of such a vaccine in AD mouse models of amyloid deposition. It should be noted, however, that several studies using passive immunization specifically targeting A&#x03B2;pE3 have already been conducted in different mouse amyloid models. These studies provided solid and concordant evidence that anti-A&#x03B2;pE3 antibodies have an overall plaque lowering effect and can improve the associated cognitive/behavioral deficits (<xref ref-type="bibr" rid="c10">Demattos et al. 2012</xref>; <xref ref-type="bibr" rid="c11">Frost et al. 2015</xref>; <xref ref-type="bibr" rid="c42">Wirths et al. 2010</xref>). Thus, it will be important to determine whether selective and active anti-A&#x03B2;pE3 immunization could also reduce the pathology in these models.</p>
<p>In this context, new immunization formulations for the A&#x03B2;pE3:CRM197 vaccine will have to be tested to boost antibody production. Indeed, although the A&#x03B2;pE3:CRM197 antiserum was able to react with both synthetic A&#x03B2;pE3 and AD-brain derived amyloid material, its antibody levels in the serum around 1.5 &#x03BC;g/mL are likely to be too low to allow clearance of A&#x03B2;pE3 and amyloid in mouse AD models. Thus, future experiments will also have to determine whether immunogenicity of the A&#x03B2;pE3:CRM197 vaccine can be improved by repeated injections and/or addition of adjuvants. Interestingly, recent data demonstrated that combined addition of the adjuvants aluminum hydroxide and CpG can increase more than 100-fold the antibody titer of a nicotine:CRM197 conjugate vaccine (<xref ref-type="bibr" rid="c20">McCluskie et al. 2015</xref>) and QS-21 elicited consistently higher anti-A&#x03B2; IgG titers in a phase IIa trial for the A&#x03B2;1-6:CRM197 ACC-001 vaccine (<xref ref-type="bibr" rid="c23">Pasquier et al. 2016</xref>).</p>
<p>In conclusion, we propose that conjugation of peptides A&#x03B2;pE3-8 and A&#x03B2;pE11-16 to CRM197 can generate fully specific vaccines directed against A&#x03B2;pE3 and A&#x03B2;pE11, respectively. The main strength of this immunization strategy is to combine the advantages of a vaccine with the high specificity of targeting particularly amyloidogenic and neurotoxic sub-species of A&#x03B2;, while sparing the more abundant and maybe more physiologically relevant full-length A&#x03B2;40 and A&#x03B2;42.</p>
</sec>
</body>
<back>
<ref-list>
<title>REFERENCES</title>
<ref id="c1"><mixed-citation publication-type="journal"><string-name><surname>Alexandru</surname> <given-names>A</given-names></string-name>, <string-name><surname>Jagla</surname> <given-names>W</given-names></string-name>, <string-name><surname>Graubner</surname> <given-names>S</given-names></string-name>, <string-name><surname>Becker</surname> <given-names>A</given-names></string-name>, <string-name><surname>B&#x00E4;uscher</surname> <given-names>C</given-names></string-name>, <string-name><surname>Kohlmann</surname> <given-names>S</given-names></string-name>, <string-name><surname>Sedlmeier</surname> <given-names>R</given-names></string-name>, <string-name><surname>Raber</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Cynis</surname> <given-names>H</given-names></string-name>, <string-name><surname>R&#x00F6;nicke</surname> <given-names>R</given-names></string-name>, <string-name><surname>Reymann</surname> <given-names>KG</given-names></string-name>, <string-name><surname>Petrasch-Parwez</surname> <given-names>E</given-names></string-name>, <string-name><surname>Hartlage-R&#x00FC;bsamen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Waniek</surname> <given-names>A</given-names></string-name>, <string-name><surname>Rossner</surname> <given-names>S</given-names></string-name>, <string-name><surname>Schilling</surname> <given-names>S</given-names></string-name>, <string-name><surname>Osmand</surname> <given-names>AP</given-names></string-name>, <string-name><surname>Demuth</surname> <given-names>HU</given-names></string-name>, and <string-name><surname>von H&#x00F6;rsten</surname> <given-names>S</given-names></string-name>. <year>2011</year>. <article-title>Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated A&#x03B2; is induced by pyroglutamate-A&#x03B2; formation</article-title>. <source>J Neurosci</source> <volume>31</volume>:<fpage>12790</fpage>-<lpage>12801</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1794-11.2011</pub-id></mixed-citation></ref>
<ref id="c2"><mixed-citation publication-type="journal"><string-name><surname>Bayer</surname> <given-names>TA</given-names></string-name>, and <string-name><surname>Wirths</surname> <given-names>O</given-names></string-name>. <year>2014</year>. <article-title>Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease</article-title>. <source>Acta Neuropathol</source> <volume>127</volume>:<fpage>787</fpage>-<lpage>801</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-014-1287-x</pub-id></mixed-citation></ref>
<ref id="c3"><mixed-citation publication-type="journal"><string-name><surname>Br&#x00F6;ker</surname> <given-names>M</given-names></string-name>, <string-name><surname>Costantino</surname> <given-names>P</given-names></string-name>, <string-name><surname>DeTora</surname> <given-names>L</given-names></string-name>, <string-name><surname>McIntosh</surname> <given-names>ED</given-names></string-name>, and <string-name><surname>Rappuoli</surname> <given-names>R</given-names></string-name>. <year>2011</year>. <article-title>Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications</article-title>. <source>Biologicals</source> <volume>39</volume>:<fpage>195</fpage>-<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1016/j.biologicals.2011.05.004</pub-id></mixed-citation></ref>
<ref id="c4"><mixed-citation publication-type="journal"><string-name><surname>Caro-Aguilar</surname> <given-names>I</given-names></string-name>, <string-name><surname>Ottinger</surname> <given-names>E</given-names></string-name>, <string-name><surname>Hepler</surname> <given-names>RW</given-names></string-name>, <string-name><surname>Nahas</surname> <given-names>DD</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>C</given-names></string-name>, <string-name><surname>Good</surname> <given-names>MF</given-names></string-name>, <string-name><surname>Batzloff</surname> <given-names>M</given-names></string-name>, <string-name><surname>Joyce</surname> <given-names>JG</given-names></string-name>, <string-name><surname>Heinrichs</surname> <given-names>JH</given-names></string-name>, and <string-name><surname>Skinner</surname> <given-names>JM</given-names></string-name>. <year>2013</year>. <article-title>Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197</article-title>. <source>Hum Vaccin Immunother</source> <volume>9</volume>:<fpage>488</fpage>-<lpage>496</lpage>.</mixed-citation></ref>
<ref id="c5"><mixed-citation publication-type="journal"><string-name><surname>Checler</surname> <given-names>F</given-names></string-name>. <year>1995</year>. <article-title>Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease</article-title>. <source>J Neurochem</source> <volume>65</volume>:<fpage>1431</fpage>-<lpage>1444</lpage>.</mixed-citation></ref>
<ref id="c6"><mixed-citation publication-type="journal"><string-name><surname>Citron</surname> <given-names>M</given-names></string-name>. <year>2010</year>. <article-title>Alzheimer's disease: strategies for disease modification</article-title>. <source>Nat Rev Drug Discov</source> <volume>9</volume>:<fpage>387</fpage>-<lpage>398</lpage>. <pub-id pub-id-type="doi">10.1038/nrd2896</pub-id></mixed-citation></ref>
<ref id="c7"><mixed-citation publication-type="journal"><string-name><surname>Cynis</surname> <given-names>H</given-names></string-name>, <string-name><surname>Frost</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Crehan</surname> <given-names>H</given-names></string-name>, and <string-name><surname>Lemere</surname> <given-names>CA.</given-names></string-name> <year>2016</year>. <article-title>Immunotherapy targeting pyroglutamate-3 A&#x03B2;: prospects and challenges</article-title>. <source>Mol Neurodegener</source> <volume>11</volume>:<fpage>48</fpage>. <pub-id pub-id-type="doi">10.1186/s13024-016-0115-2</pub-id></mixed-citation></ref>
<ref id="c8"><mixed-citation publication-type="journal"><string-name><surname>Dammers</surname> <given-names>C</given-names></string-name>, <string-name><surname>Gremer</surname> <given-names>L</given-names></string-name>, <string-name><surname>Rei&#x00DF;</surname> <given-names>K</given-names></string-name>, <string-name><surname>Klein</surname> <given-names>AN</given-names></string-name>, <string-name><surname>Neudecker</surname> <given-names>P</given-names></string-name>, <string-name><surname>Hartmann</surname> <given-names>R</given-names></string-name>, <string-name><surname>Sun</surname> <given-names>N</given-names></string-name>, <string-name><surname>Demuth</surname> <given-names>HU</given-names></string-name>, <string-name><surname>Schwarten</surname> <given-names>M</given-names></string-name>, and <string-name><surname>Willbold</surname> <given-names>D.</given-names></string-name> <year>2015</year>. <article-title>Structural Analysis and Aggregation Propensity of Pyroglutamate A&#x03B2;(3-40) in Aqueous Trifluoroethanol</article-title>. <source>PLoS One</source> <volume>10</volume>:<fpage>e0143647</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0143647</pub-id></mixed-citation></ref>
<ref id="c9"><mixed-citation publication-type="journal"><string-name><surname>De Strooper</surname> <given-names>B</given-names></string-name>, <string-name><surname>Vassar</surname> <given-names>R</given-names></string-name>, and <string-name><surname>Golde</surname> <given-names>T.</given-names></string-name> <year>2010</year>. <article-title>The secretases: enzymes with therapeutic potential in Alzheimer disease</article-title>. <source>Nat Rev Neurol</source> <volume>6</volume>:<fpage>99</fpage>-<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2009.218</pub-id></mixed-citation></ref>
<ref id="c10"><mixed-citation publication-type="journal"><string-name><surname>Demattos</surname> <given-names>RB</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Tang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Racke</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Delong</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Tzaferis</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Hole</surname> <given-names>JT</given-names></string-name>, <string-name><surname>Forster</surname> <given-names>BM</given-names></string-name>, <string-name><surname>McDonnell</surname> <given-names>PC</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>F</given-names></string-name>, <string-name><surname>Kinley</surname> <given-names>RD</given-names></string-name>, <string-name><surname>Jordan</surname> <given-names>WH</given-names></string-name>, and <string-name><surname>Hutton</surname> <given-names>ML</given-names></string-name>. <year>2012</year>. <article-title>A plaque-specific antibody clears existing &#x03B2;-amyloid plaques in Alzheimer's disease mice</article-title>. <source>Neuron</source> <volume>76</volume>:<fpage>908</fpage>-<lpage>920</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2012.10.029</pub-id></mixed-citation></ref>
<ref id="c11"><mixed-citation publication-type="journal"><string-name><surname>Frost</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>B</given-names></string-name>, <string-name><surname>Rahfeld</surname> <given-names>JU</given-names></string-name>, <string-name><surname>Kleinschmidt</surname> <given-names>M</given-names></string-name>, <string-name><surname>O'Nuallain</surname> <given-names>B</given-names></string-name>, <string-name><surname>Le</surname> <given-names>KX</given-names></string-name>, <string-name><surname>Lues</surname> <given-names>I</given-names></string-name>, <string-name><surname>Caldarone</surname> <given-names>BJ</given-names></string-name>, <string-name><surname>Schilling</surname> <given-names>S</given-names></string-name>, <string-name><surname>Demuth</surname> <given-names>HU</given-names></string-name>, and <string-name><surname>Lemere</surname> <given-names>CA</given-names></string-name>. <year>2015</year>. <article-title>An anti-pyroglutamate-3 A&#x03B2; vaccine reduces plaques and improves cognition in APPswe/PS1&#x0394;E9 mice</article-title>. <source>Neurobiol Aging</source> <volume>36</volume>:<fpage>3187</fpage>-<lpage>3199</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2015.08.021</pub-id></mixed-citation></ref>
<ref id="c12"><mixed-citation publication-type="journal"><string-name><surname>Golde</surname> <given-names>TE</given-names></string-name>. <year>2014</year>. <article-title>Open questions for Alzheimer's disease immunotherapy</article-title>. <source>Alzheimers Res Ther</source> <volume>6</volume>:<fpage>3</fpage>. <pub-id pub-id-type="doi">10.1186/alzrt233</pub-id></mixed-citation></ref>
<ref id="c13"><mixed-citation publication-type="journal"><string-name><surname>Gunn</surname> <given-names>AP</given-names></string-name>, <string-name><surname>Wong</surname> <given-names>BX</given-names></string-name>, <string-name><surname>Johanssen</surname> <given-names>T</given-names></string-name>, <string-name><surname>Griffith</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Masters</surname> <given-names>CL</given-names></string-name>, <string-name><surname>Bush</surname> <given-names>AI</given-names></string-name>, <string-name><surname>Barnham</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Duce</surname> <given-names>JA</given-names></string-name>, and <string-name><surname>Cherny</surname> <given-names>RA</given-names></string-name>. <year>2016</year>. <article-title>Amyloid-&#x03B2; Peptide A&#x03B2;3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons</article-title>. <source>J Biol Chem</source> <volume>291</volume>:<fpage>6134</fpage>-<lpage>6145</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M115.655183</pub-id></mixed-citation></ref>
<ref id="c14"><mixed-citation publication-type="journal"><string-name><surname>Hampel</surname> <given-names>H</given-names></string-name>, <string-name><surname>Schneider</surname> <given-names>LS</given-names></string-name>, <string-name><surname>Giacobini</surname> <given-names>E</given-names></string-name>, <string-name><surname>Kivipelto</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sindi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Dubois</surname> <given-names>B</given-names></string-name>, <string-name><surname>Broich</surname> <given-names>K</given-names></string-name>, <string-name><surname>Nistic&#x00F2;</surname> <given-names>R</given-names></string-name>, <string-name><surname>Aisen</surname> <given-names>PS</given-names></string-name>, and <string-name><surname>Lista</surname> <given-names>S.</given-names></string-name> <year>2015</year>. <article-title>Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future</article-title>. <source>Expert Rev Neurother</source> <volume>15</volume>:<fpage>83</fpage>-<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1586/14737175.2015.995637</pub-id></mixed-citation></ref>
<ref id="c15"><mixed-citation publication-type="journal"><string-name><surname>He</surname> <given-names>W</given-names></string-name>, and <string-name><surname>Barrow</surname> <given-names>CJ.</given-names></string-name> <year>1999</year>. <article-title>The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta</article-title>. <source>Biochemistry</source> <volume>38</volume>:<fpage>10871</fpage>-<lpage>10877</lpage>. <pub-id pub-id-type="doi">10.1021/bi990563r</pub-id></mixed-citation></ref>
<ref id="c16"><mixed-citation publication-type="journal"><string-name><surname>Holmes</surname> <given-names>C</given-names></string-name>, <string-name><surname>Boche</surname> <given-names>D</given-names></string-name>, <string-name><surname>Wilkinson</surname> <given-names>D</given-names></string-name>, <string-name><surname>Yadegarfar</surname> <given-names>G</given-names></string-name>, <string-name><surname>Hopkins</surname> <given-names>V</given-names></string-name>, <string-name><surname>Bayer</surname> <given-names>A</given-names></string-name>, <string-name><surname>Jones</surname> <given-names>RW</given-names></string-name>, <string-name><surname>Bullock</surname> <given-names>R</given-names></string-name>, <string-name><surname>Love</surname> <given-names>S</given-names></string-name>, <string-name><surname>Neal</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Zotova</surname> <given-names>E</given-names></string-name>, and <string-name><surname>Nicoll</surname> <given-names>JA.</given-names></string-name> <year>2008</year>. <article-title>Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial</article-title>. <source>Lancet</source> <volume>372</volume>:<fpage>216</fpage>-<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(08)61075-2</pub-id></mixed-citation></ref>
<ref id="c17"><mixed-citation publication-type="journal"><string-name><surname>Karran</surname> <given-names>E</given-names></string-name>, and <string-name><surname>Hardy</surname> <given-names>J.</given-names></string-name> <year>2014</year>. <article-title>A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease</article-title>. <source>Ann Neurol</source> <volume>76</volume>:<fpage>185</fpage>-<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1002/ana.24188</pub-id></mixed-citation></ref>
<ref id="c18"><mixed-citation publication-type="journal"><string-name><surname>Lemere</surname> <given-names>CA</given-names></string-name>. <year>2013</year>. <article-title>Immunotherapy for Alzheimer's disease: hoops and hurdles</article-title>. <source>Mol Neurodegener</source> <volume>8</volume>:<fpage>36</fpage>. <pub-id pub-id-type="doi">10.1186/1750-1326-8-36</pub-id></mixed-citation></ref>
<ref id="c19"><mixed-citation publication-type="journal"><string-name><surname>Marambaud</surname> <given-names>P</given-names></string-name>, and <string-name><surname>Robakis</surname> <given-names>NK.</given-names></string-name> <year>2005</year>. <article-title>Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation</article-title>. <source>Genes Brain Behav</source> <volume>4</volume>:<fpage>134</fpage>-<lpage>146</lpage>. <pub-id pub-id-type="doi">10.1111/j.1601-183X.2005.00086.x</pub-id></mixed-citation></ref>
<ref id="c20"><mixed-citation publication-type="journal"><string-name><surname>McCluskie</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Thorn</surname> <given-names>J</given-names></string-name>, <string-name><surname>Gervais</surname> <given-names>DP</given-names></string-name>, <string-name><surname>Stead</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>N</given-names></string-name>, <string-name><surname>Benoit</surname> <given-names>M</given-names></string-name>, <string-name><surname>Cartier</surname> <given-names>J</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>IJ</given-names></string-name>, <string-name><surname>Bhattacharya</surname> <given-names>K</given-names></string-name>, <string-name><surname>Finneman</surname> <given-names>JI</given-names></string-name>, <string-name><surname>Merson</surname> <given-names>JR</given-names></string-name>, and <string-name><surname>Davis</surname> <given-names>HL.</given-names></string-name> <year>2015</year>. <article-title>Anti-nicotine vaccines: Comparison of adjuvanted CRM197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates</article-title>. <source>Int Immunopharmacol</source> <volume>29</volume>:<fpage>663</fpage>-<lpage>671</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2015.09.012</pub-id></mixed-citation></ref>
<ref id="c21"><mixed-citation publication-type="journal"><string-name><surname>Mori</surname> <given-names>H</given-names></string-name>, <string-name><surname>Takio</surname> <given-names>K</given-names></string-name>, <string-name><surname>Ogawara</surname> <given-names>M</given-names></string-name>, and <string-name><surname>Selkoe</surname> <given-names>DJ.</given-names></string-name> <year>1992</year>. <article-title>Mass spectrometry of purified amyloid beta protein in Alzheimer's disease</article-title>. <source>J Biol Chem</source> <volume>267</volume>:<fpage>17082</fpage>-<lpage>17086</lpage>.</mixed-citation></ref>
<ref id="c22"><mixed-citation publication-type="journal"><string-name><surname>Nussbaum</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Schilling</surname> <given-names>S</given-names></string-name>, <string-name><surname>Cynis</surname> <given-names>H</given-names></string-name>, <string-name><surname>Silva</surname> <given-names>A</given-names></string-name>, <string-name><surname>Swanson</surname> <given-names>E</given-names></string-name>, <string-name><surname>Wangsanut</surname> <given-names>T</given-names></string-name>, <string-name><surname>Tayler</surname> <given-names>K</given-names></string-name>, <string-name><surname>Wiltgen</surname> <given-names>B</given-names></string-name>, <string-name><surname>Hatami</surname> <given-names>A</given-names></string-name>, <string-name><surname>R&#x00F6;nicke</surname> <given-names>R</given-names></string-name>, <string-name><surname>Reymann</surname> <given-names>K</given-names></string-name>, <string-name><surname>Hutter-Paier</surname> <given-names>B</given-names></string-name>, <string-name><surname>Alexandru</surname> <given-names>A</given-names></string-name>, <string-name><surname>Jagla</surname> <given-names>W</given-names></string-name>, <string-name><surname>Graubner</surname> <given-names>S</given-names></string-name>, <string-name><surname>Glabe</surname> <given-names>CG</given-names></string-name>, <string-name><surname>Demuth</surname> <given-names>HU</given-names></string-name>, and <string-name><surname>Bloom</surname> <given-names>GS.</given-names></string-name> <year>2012</year>. <article-title>Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-&#x03B2;</article-title>. <source>Nature</source> <volume>485</volume>:<fpage>651</fpage>-<lpage>655</lpage>. <pub-id pub-id-type="doi">10.1038/nature11060</pub-id></mixed-citation></ref>
<ref id="c23"><mixed-citation publication-type="journal"><string-name><surname>Pasquier</surname> <given-names>F</given-names></string-name>, <string-name><surname>Sadowsky</surname> <given-names>C</given-names></string-name>, <string-name><surname>Holstein</surname> <given-names>A</given-names></string-name>, <string-name><surname>Leterme</surname> <given-names>GL</given-names></string-name>, <string-name><surname>Peng</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Jackson</surname> <given-names>N</given-names></string-name>, <string-name><surname>Fox</surname> <given-names>NC</given-names></string-name>, <string-name><surname>Ketter</surname> <given-names>N</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>E</given-names></string-name>, and <string-name><surname>Ryan</surname> <given-names>JM.</given-names></string-name> <year>2016</year>. <article-title>Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease</article-title>. <source>J Alzheimers Dis</source>. <pub-id pub-id-type="doi">10.3233/jad-150376</pub-id></mixed-citation></ref>
<ref id="c24"><mixed-citation publication-type="journal"><string-name><surname>Piccini</surname> <given-names>A</given-names></string-name>, <string-name><surname>Russo</surname> <given-names>C</given-names></string-name>, <string-name><surname>Gliozzi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Relini</surname> <given-names>A</given-names></string-name>, <string-name><surname>Vitali</surname> <given-names>A</given-names></string-name>, <string-name><surname>Borghi</surname> <given-names>R</given-names></string-name>, <string-name><surname>Giliberto</surname> <given-names>L</given-names></string-name>, <string-name><surname>Armirotti</surname> <given-names>A</given-names></string-name>, <string-name><surname>D'Arrigo</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bachi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Cattaneo</surname> <given-names>A</given-names></string-name>, <string-name><surname>Canale</surname> <given-names>C</given-names></string-name>, <string-name><surname>Torrassa</surname> <given-names>S</given-names></string-name>, <string-name><surname>Saido</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Markesbery</surname> <given-names>W</given-names></string-name>, <string-name><surname>Gambetti</surname> <given-names>P</given-names></string-name>, and <string-name><surname>Tabaton</surname> <given-names>M.</given-names></string-name> <year>2005</year>. <article-title>beta-amyloid is different in normal aging and in Alzheimer disease</article-title>. <source>J Biol Chem</source> <volume>280</volume>:<fpage>34186</fpage>-<lpage>34192</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M501694200</pub-id></mixed-citation></ref>
<ref id="c25"><mixed-citation publication-type="journal"><string-name><surname>Portelius</surname> <given-names>E</given-names></string-name>, <string-name><surname>Bogdanovic</surname> <given-names>N</given-names></string-name>, <string-name><surname>Gustavsson</surname> <given-names>MK</given-names></string-name>, <string-name><surname>Volkmann</surname> <given-names>I</given-names></string-name>, <string-name><surname>Brinkmalm</surname> <given-names>G</given-names></string-name>, <string-name><surname>Zetterberg</surname> <given-names>H</given-names></string-name>, <string-name><surname>Winblad</surname> <given-names>B</given-names></string-name>, and <string-name><surname>Blennow</surname> <given-names>K.</given-names></string-name> <year>2010</year>. <article-title>Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease</article-title>. <source>Acta Neuropathol</source> <volume>120</volume>:<fpage>185</fpage>-<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-010-0690-1</pub-id></mixed-citation></ref>
<ref id="c26"><mixed-citation publication-type="journal"><string-name><surname>Rammensee</surname> <given-names>HG</given-names></string-name>. <year>1995</year>. <article-title>Chemistry of peptides associated with MHC class I and class II molecules</article-title>. <source>Curr Opin Immunol</source> <volume>7</volume>:<fpage>85</fpage>-<lpage>96</lpage>.</mixed-citation></ref>
<ref id="c27"><mixed-citation publication-type="journal"><string-name><surname>Rondini</surname> <given-names>S</given-names></string-name>, <string-name><surname>Micoli</surname> <given-names>F</given-names></string-name>, <string-name><surname>Lanzilao</surname> <given-names>L</given-names></string-name>, <string-name><surname>Hale</surname> <given-names>C</given-names></string-name>, <string-name><surname>Saul</surname> <given-names>AJ</given-names></string-name>, and <string-name><surname>Martin</surname> <given-names>LB.</given-names></string-name> <year>2011</year>. <article-title>Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi</article-title>. <source>Clin Vaccine Immunol</source> <volume>18</volume>:<fpage>460</fpage>-<lpage>468</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00387-10</pub-id></mixed-citation></ref>
<ref id="c28"><mixed-citation publication-type="journal"><string-name><surname>Russo</surname> <given-names>C</given-names></string-name>, <string-name><surname>Violani</surname> <given-names>E</given-names></string-name>, <string-name><surname>Salis</surname> <given-names>S</given-names></string-name>, <string-name><surname>Venezia</surname> <given-names>V</given-names></string-name>, <string-name><surname>Dolcini</surname> <given-names>V</given-names></string-name>, <string-name><surname>Damonte</surname> <given-names>G</given-names></string-name>, <string-name><surname>Benatti</surname> <given-names>U</given-names></string-name>, <string-name><surname>D'Arrigo</surname> <given-names>C</given-names></string-name>, <string-name><surname>Patrone</surname> <given-names>E</given-names></string-name>, <string-name><surname>Carlo</surname> <given-names>P</given-names></string-name>, and <string-name><surname>Schettini</surname> <given-names>G.</given-names></string-name> <year>2002</year>. <article-title>Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival</article-title>. <source>J Neurochem</source> <volume>82</volume>:<fpage>1480</fpage>-<lpage>1489</lpage>.</mixed-citation></ref>
<ref id="c29"><mixed-citation publication-type="journal"><string-name><surname>Saido</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Iwatsubo</surname> <given-names>T</given-names></string-name>, <string-name><surname>Mann</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Shimada</surname> <given-names>H</given-names></string-name>, <string-name><surname>Ihara</surname> <given-names>Y</given-names></string-name>, and <string-name><surname>Kawashima</surname> <given-names>S.</given-names></string-name> <year>1995</year>. <article-title>Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques</article-title>. <source>Neuron</source> <volume>14</volume>:<fpage>457</fpage>-<lpage>466</lpage>.</mixed-citation></ref>
<ref id="c30"><mixed-citation publication-type="journal"><string-name><surname>Schilling</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lauber</surname> <given-names>T</given-names></string-name>, <string-name><surname>Schaupp</surname> <given-names>M</given-names></string-name>, <string-name><surname>Manhart</surname> <given-names>S</given-names></string-name>, <string-name><surname>Scheel</surname> <given-names>E</given-names></string-name>, <string-name><surname>B&#x00F6;hm</surname> <given-names>G</given-names></string-name>, and <string-name><surname>Demuth</surname> <given-names>HU.</given-names></string-name> <year>2006</year>. <article-title>On the seeding and oligomerization of pGlu-amyloid peptides (in vitro)</article-title>. <source>Biochemistry</source> <volume>45</volume>:<fpage>12393</fpage>-<lpage>12399</lpage>. <pub-id pub-id-type="doi">10.1021/bi0612667</pub-id></mixed-citation></ref>
<ref id="c31"><mixed-citation publication-type="journal"><string-name><surname>Schilling</surname> <given-names>S</given-names></string-name>, <string-name><surname>Zeitschel</surname> <given-names>U</given-names></string-name>, <string-name><surname>Hoffmann</surname> <given-names>T</given-names></string-name>, <string-name><surname>Heiser</surname> <given-names>U</given-names></string-name>, <string-name><surname>Francke</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kehlen</surname> <given-names>A</given-names></string-name>, <string-name><surname>Holzer</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hutter-Paier</surname> <given-names>B</given-names></string-name>, <string-name><surname>Prokesch</surname> <given-names>M</given-names></string-name>, <string-name><surname>Windisch</surname> <given-names>M</given-names></string-name>, <string-name><surname>Jagla</surname> <given-names>W</given-names></string-name>, <string-name><surname>Schlenzig</surname> <given-names>D</given-names></string-name>, <string-name><surname>Lindner</surname> <given-names>C</given-names></string-name>, <string-name><surname>Rudolph</surname> <given-names>T</given-names></string-name>, <string-name><surname>Reuter</surname> <given-names>G</given-names></string-name>, <string-name><surname>Cynis</surname> <given-names>H</given-names></string-name>, <string-name><surname>Montag</surname> <given-names>D</given-names></string-name>, <string-name><surname>Demuth</surname> <given-names>HU</given-names></string-name>, and <string-name><surname>Rossner</surname> <given-names>S.</given-names></string-name> <year>2008</year>. <article-title>Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology</article-title>. <source>Nat Med</source> <volume>14</volume>:<fpage>1106</fpage>-<lpage>1111</lpage>. <pub-id pub-id-type="doi">10.1038/nm.1872</pub-id></mixed-citation></ref>
<ref id="c32"><mixed-citation publication-type="journal"><string-name><surname>Schlenzig</surname> <given-names>D</given-names></string-name>, <string-name><surname>Manhart</surname> <given-names>S</given-names></string-name>, <string-name><surname>Cinar</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Kleinschmidt</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hause</surname> <given-names>G</given-names></string-name>, <string-name><surname>Willbold</surname> <given-names>D</given-names></string-name>, <string-name><surname>Funke</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Schilling</surname> <given-names>S</given-names></string-name>, and <string-name><surname>Demuth</surname> <given-names>HU.</given-names></string-name> <year>2009</year>. <article-title>Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides</article-title>. <source>Biochemistry</source> <volume>48</volume>:<fpage>7072</fpage>-<lpage>7078</lpage>. <pub-id pub-id-type="doi">10.1021/bi900818a</pub-id></mixed-citation></ref>
<ref id="c33"><mixed-citation publication-type="journal"><string-name><surname>Schlenzig</surname> <given-names>D</given-names></string-name>, <string-name><surname>R&#x00F6;nicke</surname> <given-names>R</given-names></string-name>, <string-name><surname>Cynis</surname> <given-names>H</given-names></string-name>, <string-name><surname>Ludwig</surname> <given-names>HH</given-names></string-name>, <string-name><surname>Scheel</surname> <given-names>E</given-names></string-name>, <string-name><surname>Reymann</surname> <given-names>K</given-names></string-name>, <string-name><surname>Saido</surname> <given-names>T</given-names></string-name>, <string-name><surname>Hause</surname> <given-names>G</given-names></string-name>, <string-name><surname>Schilling</surname> <given-names>S</given-names></string-name>, and <string-name><surname>Demuth</surname> <given-names>HU.</given-names></string-name> <year>2012</year>. <article-title>N-Terminal pyroglutamate formation of A&#x03B2;38 and A&#x03B2;40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation</article-title>. <source>J Neurochem1</source> <volume>121</volume>:<fpage>774</fpage>-<lpage>784</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2012.07707.x</pub-id></mixed-citation></ref>
<ref id="c34"><mixed-citation publication-type="journal"><string-name><surname>Selkoe</surname> <given-names>DJ</given-names></string-name>. <year>2001</year>. <article-title>Alzheimer's disease: genes, proteins, and therapy</article-title>. <source>Physiol Rev</source> <volume>81</volume>:<fpage>741</fpage>-<lpage>766</lpage>.</mixed-citation></ref>
<ref id="c35"><mixed-citation publication-type="journal"><string-name><surname>Sevalle</surname> <given-names>J</given-names></string-name>, <string-name><surname>Amoyel</surname> <given-names>A</given-names></string-name>, <string-name><surname>Robert</surname> <given-names>P</given-names></string-name>, <string-name><surname>Fourni&#x00E9;-Zaluski</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Roques</surname> <given-names>B</given-names></string-name>, and <string-name><surname>Checler</surname> <given-names>F.</given-names></string-name> <year>2009</year>. <article-title>Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide</article-title>. <source>J Neurochem</source> <volume>109</volume>:<fpage>248</fpage>-<lpage>256</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.05950.x</pub-id></mixed-citation></ref>
<ref id="c36"><mixed-citation publication-type="journal"><string-name><surname>Shinefield</surname> <given-names>HR</given-names></string-name>. <year>2010</year>. <article-title>Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use</article-title>. <source>Vaccine</source> <volume>28</volume>:<fpage>4335</fpage>-<lpage>4339</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2010.04.072</pub-id></mixed-citation></ref>
<ref id="c37"><mixed-citation publication-type="journal"><string-name><surname>Sullivan</surname> <given-names>CP</given-names></string-name>, <string-name><surname>Berg</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Elliott-Bryant</surname> <given-names>R</given-names></string-name>, <string-name><surname>Fishman</surname> <given-names>JB</given-names></string-name>, <string-name><surname>McKee</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Morin</surname> <given-names>PJ</given-names></string-name>, <string-name><surname>Shia</surname> <given-names>MA</given-names></string-name>, and <string-name><surname>Fine</surname> <given-names>RE.</given-names></string-name> <year>2011</year>. <article-title>Pyroglutamate-A&#x03B2; 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-A&#x03B2; 11 forming the central core</article-title>. <source>Neurosci Lett</source> <volume>505</volume>:<fpage>109</fpage>-<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2011.09.071</pub-id></mixed-citation></ref>
<ref id="c38"><mixed-citation publication-type="journal"><string-name><surname>Tabira</surname> <given-names>T</given-names></string-name>. <year>2010</year>. <article-title>Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies</article-title>. <source>Tohoku J Exp Med</source> <volume>220</volume>:<fpage>95</fpage>-<lpage>106</lpage>.</mixed-citation></ref>
<ref id="c39"><mixed-citation publication-type="journal"><string-name><surname>Vingtdeux</surname> <given-names>V</given-names></string-name>, <string-name><surname>Chandakkar</surname> <given-names>P</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>H</given-names></string-name>, <string-name><surname>Blanc</surname> <given-names>L</given-names></string-name>, <string-name><surname>Ruiz</surname> <given-names>S</given-names></string-name>, and <string-name><surname>Marambaud</surname> <given-names>P.</given-names></string-name> <year>2015</year>. <article-title>CALHM1 ion channel elicits amyloid-&#x03B2; clearance by insulin-degrading enzyme in cell lines and in vivo in the mouse brain</article-title>. <source>J Cell Sci</source> <volume>128</volume>:<fpage>2330</fpage>-<lpage>2338</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.167270</pub-id></mixed-citation></ref>
<ref id="c40"><mixed-citation publication-type="journal"><string-name><surname>Vingtdeux</surname> <given-names>V</given-names></string-name>, <string-name><surname>Davies</surname> <given-names>P</given-names></string-name>, <string-name><surname>Dickson</surname> <given-names>DW</given-names></string-name>, and <string-name><surname>Marambaud</surname> <given-names>P.</given-names></string-name> <year>2011</year>. <article-title>AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies</article-title>. <source>Acta Neuropathol</source> <volume>121</volume>:<fpage>337</fpage>-<lpage>349</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-010-0759-x</pub-id></mixed-citation></ref>
<ref id="c41"><mixed-citation publication-type="journal"><string-name><surname>Winblad</surname> <given-names>B</given-names></string-name>, <string-name><surname>Graf</surname> <given-names>A</given-names></string-name>, <string-name><surname>Riviere</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Andreasen</surname> <given-names>N</given-names></string-name>, and <string-name><surname>Ryan</surname> <given-names>JM.</given-names></string-name> <year>2014</year>. <article-title>Active immunotherapy options for Alzheimer's disease</article-title>. <source>Alzheimers Res Ther</source> <volume>6</volume>:<fpage>7</fpage>. <pub-id pub-id-type="doi">10.1186/alzrt237</pub-id></mixed-citation></ref>
<ref id="c42"><mixed-citation publication-type="journal"><string-name><surname>Wirths</surname> <given-names>O</given-names></string-name>, <string-name><surname>Erck</surname> <given-names>C</given-names></string-name>, <string-name><surname>Martens</surname> <given-names>H</given-names></string-name>, <string-name><surname>Harmeier</surname> <given-names>A</given-names></string-name>, <string-name><surname>Geumann</surname> <given-names>C</given-names></string-name>, <string-name><surname>Jawhar</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kumar</surname> <given-names>S</given-names></string-name>, <string-name><surname>Multhaup</surname> <given-names>G</given-names></string-name>, <string-name><surname>Walter</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ingelsson</surname> <given-names>M</given-names></string-name>, <string-name><surname>Degerman-Gunnarsson</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kalimo</surname> <given-names>H</given-names></string-name>, <string-name><surname>Huitinga</surname> <given-names>I</given-names></string-name>, <string-name><surname>Lannfelt</surname> <given-names>L</given-names></string-name>, and <string-name><surname>Bayer</surname> <given-names>TA.</given-names></string-name> <year>2010</year>. <article-title>Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis</article-title>. <source>J Biol Chem</source> <volume>285</volume>:<fpage>41517</fpage>-<lpage>41524</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110.178707</pub-id></mixed-citation></ref>
<ref id="c43"><mixed-citation publication-type="journal"><string-name><surname>Wisniewski</surname> <given-names>T</given-names></string-name>, and <string-name><surname>Go&#x00F1;i</surname> <given-names>F.</given-names></string-name> <year>2015</year>. <article-title>Immunotherapeutic approaches for Alzheimer's disease</article-title>. <source>Neuron</source> <volume>85</volume>:<fpage>1162</fpage>-<lpage>1176</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2014.12.064</pub-id></mixed-citation></ref>
</ref-list>
<sec id="s5">
<table-wrap id="utbl1" orientation="portrait" position="float">
<label>Table:</label>
<caption><title>Human cases analyzed in this study</title>
<p>AD, Alzheimer&#x2019;s disease; Mid-Temp Cortex, mid-temporal cortex; Hp, hippocampal region. Cases were obtained from the Albert Einstein College of Medicine human brain bank, Bronx, NY.</p></caption>
<graphic xlink:href="084913_utbl1.tif"/>
</table-wrap>
</sec>
</back>
</article>